Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:KYMR NASDAQ:LNTH NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$55.67-2.4%$62.22$11.40▼$72.36$1.62B0.79778,682 shs295,902 shsKYMRKymera Therapeutics$81.67+0.3%$83.29$28.50▼$103.00$6.72B2.06660,219 shs303,266 shsLNTHLantheus$99.43-0.2%$85.28$47.25▼$103.89$6.45B-0.08958,240 shs913,367 shsPTGXProtagonist Therapeutics$100.00-0.4%$101.68$45.43▼$107.84$6.45B1.89730,844 shs279,371 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-1.16%-5.61%-13.75%+3.58%+172.82%KYMRKymera Therapeutics-0.29%+1.05%-2.85%-10.83%+182.85%LNTHLantheus+0.53%+5.45%+19.23%+32.99%+34.29%PTGXProtagonist Therapeutics-1.76%-1.57%-0.79%+9.05%+119.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$55.67-2.4%$62.22$11.40▼$72.36$1.62B0.79778,682 shs295,902 shsKYMRKymera Therapeutics$81.67+0.3%$83.29$28.50▼$103.00$6.72B2.06660,219 shs303,266 shsLNTHLantheus$99.43-0.2%$85.28$47.25▼$103.89$6.45B-0.08958,240 shs913,367 shsPTGXProtagonist Therapeutics$100.00-0.4%$101.68$45.43▼$107.84$6.45B1.89730,844 shs279,371 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-1.16%-5.61%-13.75%+3.58%+172.82%KYMRKymera Therapeutics-0.29%+1.05%-2.85%-10.83%+182.85%LNTHLantheus+0.53%+5.45%+19.23%+32.99%+34.29%PTGXProtagonist Therapeutics-1.76%-1.57%-0.79%+9.05%+119.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.85Moderate Buy$79.1842.25% UpsideKYMRKymera Therapeutics 2.95Moderate Buy$118.1044.59% UpsideLNTHLantheus 2.73Moderate Buy$101.862.45% UpsidePTGXProtagonist Therapeutics 2.88Moderate Buy$115.2115.22% UpsideCurrent Analyst Ratings BreakdownLatest ANAB, KYMR, LNTH, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$135.005/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$135.005/15/2026PTGXProtagonist Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/15/2026ANABAnaptysBio Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$90.005/13/2026ANABAnaptysBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026ANABAnaptysBio UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $76.005/13/2026ANABAnaptysBio BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$63.00 ➝ $75.005/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$234.60M6.90N/AN/A$0.44 per share126.51KYMRKymera Therapeutics$39.21M171.35N/AN/A$18.72 per share4.36LNTHLantheus$1.54B4.20$6.41 per share15.52$18.62 per share5.34PTGXProtagonist Therapeutics$46.02M139.74N/AN/A$10.19 per share9.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$13.23M-$1.08N/A16.04N/A-11.53%-1,101.24%-7.75%8/5/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)LNTHLantheus$233.56M$4.1523.8718.51N/A18.05%29.32%15.00%8/5/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)Latest ANAB, KYMR, LNTH, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ANABAnaptysBio-$0.6436-$1.84-$1.1965-$1.84$18.86 million$25.56 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million3/3/2026Q4 2025ANABAnaptysBio$0.89$1.58+$0.69$1.58$87.09 million$108.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A7.587.58KYMRKymera TherapeuticsN/A10.8110.81LNTHLantheus0.472.832.64PTGXProtagonist TherapeuticsN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AKYMRKymera TherapeuticsN/ALNTHLantheus99.06%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%KYMRKymera Therapeutics15.98%LNTHLantheus1.70%PTGXProtagonist Therapeutics5.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.10 million19.35 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableANAB, KYMR, LNTH, and PTGX HeadlinesRecent News About These CompaniesFisher Asset Management LLC Makes New Investment in Protagonist Therapeutics, Inc. $PTGXMay 29 at 3:49 AM | marketbeat.comProtagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026May 28 at 7:05 AM | accessnewswire.comAJ&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?May 22, 2026 | zacks.comProtagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Strong-Buy" at Wolfe ResearchMay 22, 2026 | marketbeat.comEagle Health Investments LP Takes $5.01 Million Position in Protagonist Therapeutics, Inc. $PTGXMay 21, 2026 | marketbeat.comHC Wainwright Issues Positive Outlook for PTGX EarningsMay 20, 2026 | marketbeat.comProtagonist Therapeutics Strengthens Market Buzz On Nasdaq CompositeMay 16, 2026 | kalkinemedia.comKProtagonist Therapeutics, Inc. $PTGX Holdings Raised by VIRGINIA RETIREMENT SYSTEMS ET AlMay 16, 2026 | marketbeat.comAIHC Capital Management Ltd Buys New Shares in Protagonist Therapeutics, Inc. $PTGXMay 15, 2026 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 75,000 SharesMay 13, 2026 | insidertrades.comTremfya, Icotyde Lead J&J's Post-Stelara Immunology StrategyMay 12, 2026 | zacks.comInsider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 36,000 Shares of StockMay 11, 2026 | marketbeat.comAnalyst Forecasts For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Are Surging HigherMay 11, 2026 | finance.yahoo.comState of New Jersey Common Pension Fund D Sells 20,969 Shares of Protagonist Therapeutics, Inc. $PTGXMay 11, 2026 | marketbeat.comNan Fung Trinity HK Ltd. Has $15.78 Million Stock Position in Protagonist Therapeutics, Inc. $PTGXMay 10, 2026 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Strong-Buy at Wall Street ZenMay 9, 2026 | marketbeat.comProtagonist Therapeutics, Inc. Surprised Analysts With A Profit, And Analysts Boosted Their EPS ForecastsMay 9, 2026 | finance.yahoo.comIs It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?May 7, 2026 | finance.yahoo.comProtagonist Therapeutics: Q1 Earnings SnapshotMay 6, 2026 | chron.comProtagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $137.00May 6, 2026 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Wedbush Analyst SaysMay 6, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANAB, KYMR, LNTH, and PTGX Company DescriptionsAnaptysBio NASDAQ:ANAB$55.66 -1.36 (-2.38%) As of 03:20 PM Eastern This is a fair market value price provided by Massive. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Kymera Therapeutics NASDAQ:KYMR$81.67 +0.21 (+0.26%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Lantheus NASDAQ:LNTH$99.42 -0.20 (-0.20%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$100.00 -0.42 (-0.41%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
